Key clinical point: Lebrikizumab significantly improved the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults and adolescents.
Major finding: At week 16, in the ADvocate1 and ADvocate2 trials, a significantly higher proportion of patients receiving lebrikizumab vs placebo achieved an Investigator’s Global Assessment score of 0 or 1 (43.1% vs 12.7% and 33.2% vs 10.8%, respectively) and a ≥75% improvement in the Eczema Area and Severity Index (58.8% vs 16.2% and 52.1% vs 18.1%, respectively; all P < .001). Most treatment-emergent adverse events were of mild-to-moderate severity.
Study details: Findings are from two identical phase 3 studies, ADvocate1 (n = 424) and ADvocate2 (n = 427), including adults (≥18 years) and adolescents (12 to <18 years) with moderate-to-severe AD who were randomly assigned to receive lebrikizumab or placebo over 16-week induction and 36-week maintenance periods.
Disclosures: This study was sponsored by Dermira, a wholly owned subsidiary of Eli Lilly and Company. Some authors reported various ties, including employment, with Eli Lilly or others.
Source: Silverberg JI et al for the ADvocate1 and ADvocate2 Investigators. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080-1091 (Mar 15). Doi: 10.1056/NEJMoa2206714